SEC Company Response from CASI Pharmaceuticals, Inc. (CIK 0000895051) — Nov 30, 2020

CASI Pharmaceuticals, Inc. (CIK 0000895051)
Date: Nov. 30, 2020 · CIK: 0000895051 · Accession: 0001104659-20-130458

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-250801

Date

November 30, 2020

Author

Not clearly detected

Form

CORRESP

Company

CASI Pharmaceuticals, Inc. (CIK 0000895051)

Letter

CASI Pharmaceuticals, Inc.

9620 Medical Center Drive Suite 300

Rockville, MD

Office (240) 864-2600

Fax (301) 315-2437

NASDAQ: CASI

November 30, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Mail Stop 4546

Attn: Laura Crotty

Re:

CASI Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-250801

Request for Acceleration

Ladies and Gentlemen:

CASI Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission accelerate the effective date of its Registration Statement on Form S-3 (File No. 333-250801), so that it may become effective at 4:00 p.m. Eastern Time on December 2, 2020, or as soon thereafter as practicable.

Very truly yours,
CASI PHARMACEUTICALS, INC.

Show Raw Text

CORRESP
1
filename1.htm

                                                                                                                                CASI
                                         Pharmaceuticals, Inc.

9620 Medical Center
Drive Suite 300

Rockville, MD
20850

Office (240)
864-2600

Fax (301)
315-2437

NASDAQ: CASI

November 30, 2020

VIA EDGAR

U.S. Securities and Exchange
Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Mail Stop 4546

Attn: Laura Crotty

    Re:

        CASI Pharmaceuticals, Inc.

        Registration Statement on Form S-3

        File No. 333-250801

        Request for Acceleration

Ladies and Gentlemen:

CASI Pharmaceuticals, Inc. (the “Registrant”)
hereby requests that the Securities and Exchange Commission accelerate the effective date of its Registration Statement on Form
S-3 (File No. 333-250801), so that it may become effective at 4:00 p.m. Eastern Time on December 2, 2020, or as soon thereafter
as practicable.

        Very truly yours,

        CASI PHARMACEUTICALS, INC.

        By: /s/ Cynthia W. Hu

        Name: Cynthia W. Hu

        Title: COO, General Counsel and Secretary

SecProbe.io